Search
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Taliglucerase alfa
go.drugbank.com/drugs/DB08876ApprovedIt was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.
Sulforaphane
go.drugbank.com/drugs/DB12422InvestigationalIt is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli.
Categories: Compounds used in a research, industrial, or household settingACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington … ACR-16 is also being studied in other psychiatric and neurologic diseases.
Oxyphenonium
go.drugbank.com/drugs/DB00219ApprovedIt is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]
Nefiracetam
go.drugbank.com/drugs/DB13082InvestigationalNefiracetam has been used in trials studying the treatment of Alzheimer's Disease.
Categories: Compounds used in a research, industrial, or household settingAllisartan isoproxil
go.drugbank.com/drugs/DB18880InvestigationalAllisartan isoproxil is under investigation in clinical trial NCT03264352 (Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes).
Categories: Agents Acting on the Renin-Angiotensin SystemTorcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Amibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.